230 related articles for article (PubMed ID: 22757772)
1. Relapsed multiple myeloma: who benefits from salvage autografts?
Chow AW; Lee CH; Hiwase DK; To LB; Horvath N
Intern Med J; 2013 Feb; 43(2):156-61. PubMed ID: 22757772
[TBL] [Abstract][Full Text] [Related]
2. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
3. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
4. Second autologous transplant as salvage therapy in multiple myeloma.
Atanackovic D; Schilling G
Br J Haematol; 2013 Dec; 163(5):565-72. PubMed ID: 24111632
[TBL] [Abstract][Full Text] [Related]
5. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.
Lemieux E; Hulin C; Caillot D; Tardy S; Dorvaux V; Michel J; Gastinne T; Rossi C; Legouge C; Touzeau C; Planche L; Loirat M; Lafon I; Moreau P
Biol Blood Marrow Transplant; 2013 Mar; 19(3):445-9. PubMed ID: 23186983
[TBL] [Abstract][Full Text] [Related]
7. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
8. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
[TBL] [Abstract][Full Text] [Related]
9. Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation.
Trieu Y; Trudel S; Pond GR; Mikhael J; Jaksic W; Reece DE; Chen CI; Stewart AK
Mayo Clin Proc; 2005 Dec; 80(12):1578-82. PubMed ID: 16342650
[TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
11. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
[TBL] [Abstract][Full Text] [Related]
12. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
[TBL] [Abstract][Full Text] [Related]
13. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Kröger N; Zabelina T; Klyuchnikov E; Kropff M; Pflüger KH; Burchert A; Stübig T; Wolschke C; Ayuk F; Hildebrandt Y; Bacher U; Badbaran A; Schilling G; Hansen T; Atanackovic D; Zander AR
Bone Marrow Transplant; 2013 Mar; 48(3):403-7. PubMed ID: 22863722
[TBL] [Abstract][Full Text] [Related]
14. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
15. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.
Singh Abbi KK; Zheng J; Devlin SM; Giralt S; Landau H
Biol Blood Marrow Transplant; 2015 Mar; 21(3):468-72. PubMed ID: 25529381
[TBL] [Abstract][Full Text] [Related]
16. Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant.
Goda JS; Massey C; Kuruvilla J; Gospodarowicz MK; Wells W; Hodgson DC; Sun A; Keating A; Crump M; Tsang RW
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e329-35. PubMed ID: 22672755
[TBL] [Abstract][Full Text] [Related]
17. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
[TBL] [Abstract][Full Text] [Related]
18. Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Zannetti BA; Tacchetti P; Pantani L; Gamberi B; Tosi P; Rocchi S; Cellini C; Ronconi S; Pezzi A; Mancuso K; Rizzello I; Caratozzolo I; Martello M; Dozza L; Cavo M; Zamagni E
Ann Hematol; 2017 Dec; 96(12):2071-2078. PubMed ID: 29063955
[TBL] [Abstract][Full Text] [Related]
19. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
